GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine

Regulatory Peptides

Volumn 114, Issue 2-3, 2003, Pages 189-196

  Mortensen, Kristine ^a   Christensen, Louise Lundby ^a   Holst, Jens Juul ^a   Orskov, Cathrine ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Endocrine phenotype; Glucagon like peptide 1; Glucose dependent insulinotropic polypeptide; Incretin; Peptide YY

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; PEPTIDE YY; POLYPEPTIDE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CELL SUBPOPULATION; CONTROLLED STUDY; ENDOCRINE CELL; FEMALE; GASTROINTESTINAL TRACT; HUMAN; HUMAN TISSUE; ILEUM; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; JEJUNUM; MALE; NONHUMAN; PEPTIDE ANALYSIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; RAT; SMALL INTESTINE; STAINING;

MAMMALIA; SUIDAE;

EID: 0037784011     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-0115(03)00125-3     Document Type: Article

References (34)

1. Orskov C. Glucagon-like peptide-1, a new hormone of the entero-insular axis. Diabetologia. 35:1992;701-711.
2. Ebert R., Creutzfeldt W. Gastric inhibitory polypeptide. Clin. Gastroenterol. 9:1980;679-698.
3. Adrian T.E., Ferri G.L., Bacarese-Hamilton A.J., Fuessl H.S., Polak J.M., Bloom S.R. Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology. 89:1985;1070-1077.
4. Miyawaki K., Yamada Y., Yano H., Niwa H., Ban N., Ihara Y.et al. Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. Proc. Natl. Acad. Sci. U. S. A. 96:1996;14843-14847.
5. Scrocchi L.A., Brown T.J., MaClusky N., Brubaker P.L., Auerbach A.B., Joyner A.L.et al. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat. Med. 11:1996;1254-1258.
6. Holst J.J. Glucagon-like peptide-1 (GLP-1): an intestinal hormone, signalling nutritional abundance, with an unusual therapeutic potential. TEM. 10:1999;229-235.
7. Kauth T., Metz J. Immunohistochemical localization of glucagon-like peptide: 1. Use of poly- and monoclonal antibodies. Histochemistry. 86:1987;509-515.
8. Eissele R., Goke R., Willemer S., Harthus H.P., Vermeer H., Arnold R.et al. Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man. Eur. J. Clin. Invest. 22:1992;283-291.
9. Bottcher G., Sjölund K., Ekblad E., Hakanson R., Schwartz T.W., Sundler F. Coexistence of peptide YY and glicentin immunoreactivity in endocrine cells of the gut. Regul. Pept. 8:1984;261-266.
10. Buchan A.M., Polak J.M., Capella C., Solcia E., Pearse A.G. Electroimmunocytochemical evidence for the K cell localization of gastric inhibitory polypeptide (GIP) in man. Histochemistry. 56:1987;37-44.
11. Miholic J., Orskov C., Holst J.J., Kotzerke J., Meyer H.J. Emptying of the gastric substitute, glucagon-like peptide-1 (GLP-1) and reactive hypoglycemia after total gastrectomy. Dig. Dis. Sci. 36:1991;1361-1370.
12. Dumoulin V., Dakka T., Plaisancie P., Chayvialle J.A., Cuber J.C. Regulation of glucagon-like peptide-1 (7-36) amide, peptide YY, and neurotensin secretion by neurotransmitters and gut hormones in the isolated vascularly perfused rat ileum. Endocrinology. 136:1995;5182-5188.
13. Plaisancie P., Bernard C., Chayvialle J.A., Cuber J.C. Regulation of glucagon-like peptide-1 (7-36) amide secretion by intestinal neurotransmitters and hormones in the isolated vascularly perfused rat colon. Endocrinology. 135:1994;2398-2403.
14. Herrmann-Rinke C., Voge A., Hess M., Goke B. Regulation of glucagon-like peptide-1 secretion from rat ileum by neurotransmitters and peptides. J. Endocrinol. 147:1995;25-31.
15. Roberge J.N., Brubaker P.L. Regulation of intestinal proglucagon-derived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop. Endocrinology. 133:1993;233-240.
16. Damholt A.B., Buchan A.M., Kofod H. Glucagon-like-peptide-1 secretion from canine L-cells is increased by glucose-dependent insulinotropic peptide but unaffected by glucose. Endocrinology. 139:1998;2085-2091.
17. Hansen L., Holst J.J. The effect of duodenal peptides on glucagon-like peptide-1 secretion from the ileum: a duodeno-ileal loop. Regul. Pept. 110:2002;39-45.
18. Nauck M.A., Bartels E., Orskov C., Ebert R., Creutzfeldt W. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1 (7-36) amide infused at near-physiological concentrations. J. Clin. Endocrinol. Metab. 76:1993;912-917.
19. Mortensen K., Petersen L.L., Orskov C. Colocalization of GLP-1 and GIP in human and porcine intestine. Ann. N.Y. Acad. Sci. 921:2000;469-472.
20. Moody A.J., Krarup T., Larsen U.D. The reactivity of anti-porcine gastric inhibitory polypeptide (GIP) rabbit serum R65 with synthetic human and porcine GIP. Scand. J. Clin. Lab. Invest. 52:1992;103-106.
21. Deacon C.F., Nauck M.A., Meier J., Hücking K., Holst J.J. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J. Clin. Endocrinol. Metab. 85:2000;3575-3581.
22. Orskov C., Holst J.J., Poulsen S.S., Kirkegaard P. Pancreatic and intestinal processing of proglucagon in man. Diabetologia. 30:1987;874-881.
23. Bell G.I., Santerre R.F., Mullenbach G.T. Hamster preproglucagon contains the sequence of glucagon and two related peptides. Nature. 302:1983;716-718.
24. Holst J.J., Bersani M. Assays for peptide products of somatostatin gene expression. Conn M. Methods in neurosciences: neuropeptide technology. 1991;3-22 Academic Press, San Diego.
25. Orskov C., Jeppesen J., Madsbad S., Holst J.J. Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine. J. Clin. Invest. 87:1991;415-423.
26. Orskov C., Holst J.J., Knuhtsen S., Baldissera F.G., Poulsen S.S., Nielsen O.V. Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas. Endocrinology. 119:1986;1467-1475.
27. Krarup T., Holst J.J. The heterogeneity of gastric inhibitory polypeptide in porcine and human gastrointestinal mucosa evaluated with five different antisera. Regul. Pept. 9:1984;35-46.
28. Damholt A.B., Kofod H., Buchan A.M. Immunocytochemical evidence for a paracrine interaction between GIP and GLP-1-producing cells in canine small intestine. Cell Tissue Res. 298:1999;287-293.
29. Sheikh S.P., Holst J.J., Orskov C., Ekman R., Schwartz T.W. Release of PYY from pig intestinal mucosa; luminal and neural regulation. Regul. Pept. 26:1989;253-266.
30. Lopez M.J., Upchurch B.H., Rindi G., Leiter A.B. Studies in transgenic mice reveal potential relationships between secretin-producing cells and other endocrine cell types. J. Biol. Chem. 270:1995;885-891.
31. Larsson L.I., Grimelius L., Hakanson R., Rehfeld J.F., Stadil F., Holst J.et al. Mixed endocrine pancreatic tumors producing several peptide hormones. Am. J. Pathol. 79:1975;271-284.
32. Orskov C., Wettergren A., Holst J.J. Secretion of the incretin hormones glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP) correlates with insulin secretion in normal man throughout the day. Scand. J. Gastroenterol. 31:1996;665-670.
33. Orskov C., Holst J.J., Knuhtsen S., Nielsen O.V., Sheikh S., Schwartz T.W.et al. Secretion of glicentin, glucagons-like peptide 1 and 2, neurotensin, and PYY from isolated perfused pig ileum. Front. Horm. Res. (Karger, Basel). 16:1987;137-144.
34. Wettergren A., Maina P., Boesby S., Holst J.J. Glucagon-like peptide-1 7-36 amide and peptide YY have additive inhibitory effect on gastric acid secretion in man. Scand. J. Gastroenterol. 32:1997;552-555.